surmount-1 trial tirzepatide weight loss nondiabetic non-diabetic Tirzepatide for Obesity: Highlights from the SURMOUNT-1 🔴Tirzepatide for obesity and diabetes

Instructions for Use, MOUNJARO (tirzepatide) injection

Hypersensitivity Reactions In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of ZEPBOUND-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of ZEPBOUND-treated patients compared to 2.7% of placebo-treated patients

The available doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg

We help patients understand the treatment, prepare for lifestyle changes, and stay accountable throughout the process

N., & Halker Singh, R